Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum

Clinical Nuclear Medicine

Volumn 33, Issue 10, 2008, Pages 681-687

  Britz Cunningham, Scott H ^a   Millstine, John W ^a   Gerbaudo, Victor H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Comparative activity ratios; Diagnostic imaging; FDG PET CT; Oncology; SUV analysis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BASAL GANGLION; BENIGN TUMOR; BRAIN CANCER; BRAIN CORTEX; BRAIN TUMOR; CEREBELLUM; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; HUMAN; IMAGE PROCESSING; MALIGNANT NEOPLASTIC DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIOISOTOPE DISTRIBUTION; BRAIN; COMPUTER ASSISTED DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; EVALUATION; IMAGE ENHANCEMENT; METHODOLOGY; RADIOGRAPHY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

BRAIN; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 54449084310     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318184b435     Document Type: Article

References (20)

1. Hunter GJ, Hamberg LM, Alpert NM, et al. Simplified measurement of deoxyglucose utilization rate. J Nucl Med. 1996;37:950-955.
2. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
3. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371-388.
4. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol. 2000;27:647-655.
5. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology. 1993;188:487-490.
6. Keyes JW. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-1839.
7. Smith TA. Facilitative glucose transporter expression in human cancer tissue. Br JBiomed Sci. 1999;56:285-292.
8. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35:9-26.
9. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005; 202:654-62.
10. Rahner-Welsch S, Vogel J, Kuschinsky W. Regional congruence and divergence of glucose transporters (GLUT1) and capillaries in rat brains. J Cereb Blood Flow Metab. 1995;15:681-686.
11. Vannucci SJ, Seaman LB, Brucklacher RM, et al. Glucose transport in developing rat brain: glucose transporter proteins, rate constants and cerebral glucose utilization. Mol Cell Biochem. 1994;140:170-184.
12. Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78-84.
13. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. J Clin Oncol. 1999;17:3201-3206.
14. Borst GR, Belderbos JSA, Boellard R, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533-1541.
15. Kobayashi M, Nikami H, Morimatsu M, et al. Expression and localization of insulin-regulatable glucose transporter (GLUT4) in rat brain. Neurosci Lett. 1996;213:103-106.
16. Obrzut S, Pham RH, Vera DR, et al. Comparison of lesion-to-cerebellum uptake ratios and standardized uptake values in the evaluation of lung nodules with 18F-FDG PET. Nucl Med Commun. 2007;28:7-13.
17. Buchsbaum MS, Wu J, DeLisi LE, et al. Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness. J Affect Disord. 1986;10:137-152.
18. Inagaki M, Yoshikawa E, Kobayakawa M, et al. Regional cerebral glucose metabolism in patients with secondary depressive episodes after fatal pancreatic cancer diagnosis. J Affect Disord. 2007;99:231-236.
19. Wang GJ, Volkow ND, Overall J, et al. Reproducibility of regional brain metabolic responses to lorazepam. J Nucl Med. 1996;37:1609-1613.
20. Silverman DHS, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303-311.